Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 338

1.

Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus.

Blez D, Blaize M, Soussain C, Boissonnas A, Meghraoui-Kheddar A, Menezes N, Portalier A, Combadière C, Leblond V, Ghez D, Fekkar A.

Haematologica. 2019 Jun 6. pii: haematol.2019.219220. doi: 10.3324/haematol.2019.219220. [Epub ahead of print]

2.

High-dose therapy with autologous stem cells transplantation in Bing-Neel syndrome: A retrospective analysis of 14 cases.

Simon L, Lemal R, Fornecker LM, Tournilhac O, Leblond V.

Am J Hematol. 2019 May 31. doi: 10.1002/ajh.25547. [Epub ahead of print] No abstract available.

PMID:
31149742
3.

A revised international prognostic score system for Waldenström's macroglobulinemia.

Kastritis E, Morel P, Duhamel A, Gavriatopoulou M, Kyrtsonis MC, Durot E, Symeonidis A, Laribi K, Hatjiharissi E, Ysebaert L, Vassou A, Giannakoulas N, Merlini G, Repousis P, Varettoni M, Michalis E, Hivert B, Michail M, Katodritou E, Terpos E, Leblond V, Dimopoulos MA.

Leukemia. 2019 May 22. doi: 10.1038/s41375-019-0431-y. [Epub ahead of print]

PMID:
31118465
4.

Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemia.

Kostopoulou F, Gabillaud C, Chapiro E, Grange B, Tran J, Bouzy S, Degaud M, Ghamlouch H, Le Garff-Tavernier M, Maloum K, Choquet S, Leblond V, Gabarre J, Lavaud A, Morel V, Roos-Weil D, Uzunov M, Guieze R, Bernard OA, Susin SA, Tournilhac O, Nguyen-Khac F; French Innovative Leukemia Organization (FILO) group.

Cancer Med. 2019 Jun;8(6):3131-3141. doi: 10.1002/cam4.2123. Epub 2019 May 7.

5.

A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation.

Roos-Weil D, Decaudin C, Armand M, Della-Valle V, Diop MK, Ghamlouch H, Ropars V, Hérate C, Lara D, Durot E, Haddad R, Mylonas E, Damm F, Pflumio F, Stoilova B, Metzner M, Elemento O, Dessen P, Camara-Clayette V, Cosset FL, Verhoeyen E, Leblond V, Ribrag V, Cornillet-Lefebvre P, Rameau P, Azar N, Charlotte F, Morel P, Charbonnier JB, Vyas P, Mercher T, Aoufouchi S, Droin N, Guillouf C, Nguyen-Khac F, Bernard OA.

Cancer Discov. 2019 Jun;9(6):796-811. doi: 10.1158/2159-8290.CD-18-0873. Epub 2019 Apr 24.

PMID:
31018969
6.

[Waldenström macroglobulinaemia].

Simon L, Leblond V.

Rev Prat. 2018 Sep;68(7):797-802. French.

PMID:
30869336
7.

Automated differential white blood cell count and cytological analysis can detect near-tetraploid cells in chronic lymphoproliferative disorders.

Settegrana C, Chapiro E, Frere C, Davi F, Choquet S, Leblond V, Cosson A, Nguyen-Khac F, Maloum K.

Int J Lab Hematol. 2019 Mar 4. doi: 10.1111/ijlh.12997. [Epub ahead of print] No abstract available.

PMID:
30831003
8.

How Recent Advances in Biology of Waldenström's Macroglobulinemia May Affect Therapy Strategy.

Baron M, Simon L, Poulain S, Leblond V.

Curr Oncol Rep. 2019 Feb 26;21(3):27. doi: 10.1007/s11912-019-0768-4. Review.

PMID:
30806816
9.

Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO).

Laribi K, Poulain S, Willems L, Merabet F, Le Calloch R, Eveillard JR, Herbaux C, Roos-Weil D, Chaoui D, Roussel X, Tricot S, Dupuis J, Dartigeas C, Bareau B, Bene MC, Baugier de Materre A, Leblond V.

Br J Haematol. 2018 Dec 12. doi: 10.1111/bjh.15718. [Epub ahead of print] No abstract available.

PMID:
30548257
10.

Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C.

Ann Oncol. 2019 May 1;30(5):860-862. doi: 10.1093/annonc/mdy466. No abstract available.

PMID:
30520968
11.

Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination.

Costopoulos M, Kim R, Choquet S, Maloum K, Houillier C, Algrin C, Settegrana C, Villemonteix J, Brissard M, Quiney C, Bernard S, Davi F, Thieblemont C, Hoang-Xuan K, Leblond V, Merle-Beral H, Le Garff-Tavernier M.

Semin Hematol. 2018 Oct;55(4):179-181. doi: 10.1053/j.seminhematol.2017.06.005. Epub 2017 Jul 6.

PMID:
30502843
12.

VEGF-A Inhibition as a Potential Therapeutic Approach in Merkel Cell Carcinoma.

Kervarrec T, Gaboriaud P, Tallet A, Leblond V, Arnold F, Berthon P, Schweinitzer S, Larcher T, Guyétant S, Schrama D, Houben R, Samimi M, Touzé A.

J Invest Dermatol. 2019 Mar;139(3):736-739. doi: 10.1016/j.jid.2018.08.029. Epub 2018 Oct 22. No abstract available.

PMID:
30359576
13.

Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia.

Bouyssou JM, Liu CJ, Bustoros M, Sklavenitis-Pistofidis R, Aljawai Y, Manier S, Yosef A, Sacco A, Kokubun K, Tsukamoto S, Perilla Glen A, Huynh D, Castillo JJ, Treon SP, Leblond V, Hermine O, Roccaro AM, Ghobrial IM, Capelletti M.

PLoS One. 2018 Oct 4;13(10):e0204589. doi: 10.1371/journal.pone.0204589. eCollection 2018.

14.

Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv270. doi: 10.1093/annonc/mdy322. No abstract available.

PMID:
30285219
15.

Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases.

Roux T, Debs R, Maisonobe T, Lenglet T, Delorme C, Louapre C, Leblond V, Viala K.

J Peripher Nerv Syst. 2018 Dec;23(4):235-240. doi: 10.1111/jns.12287. Epub 2018 Oct 7.

PMID:
30203907
16.

Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group.

Roos-Weil D, Nguyen-Khac F, Chevret S, Touzeau C, Roux C, Lejeune J, Cosson A, Mathis S, Feugier P, Leprêtre S, Béné MC, Baron M, Raynaud S, Struski S, Eclache V, Sutton L, Lesty C, Merle-Béral H, Cymbalista F, Ysebaert L, Davi F, Leblond V; FILO working group.

Genes Chromosomes Cancer. 2018 Nov;57(11):533-540. doi: 10.1002/gcc.22650. Epub 2018 Sep 11.

17.

Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study.

Paviglianiti A, Tozatto Maio K, Rocha V, Gehlkopf E, Milpied N, Esquirol A, Chevallier P, Blaise D, Gac AC, Leblond V, Cahn JY, Abecasis M, Zuckerman T, Schouten H, Gurman G, Rubio MT, Beguin Y, Corral LL, Nagler A, Snowden JA, Koc Y, Mordini N, Bonifazi F, Volt F, Kenzey C, Robinson SP, Montoto S, Gluckman E, Ruggeri A.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2265-2270. doi: 10.1016/j.bbmt.2018.07.019. Epub 2018 Jul 19.

18.

Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv41-iv50. doi: 10.1093/annonc/mdy146. No abstract available.

PMID:
29982402
19.

Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.

Leblond V, Aktan M, Ferra Coll CM, Dartigeas C, Kisro J, Montillo M, Raposo J, Merot JL, Robson S, Gresko E, Bosch F, Stilgenbauer S, Foà R.

Haematologica. 2018 Nov;103(11):1889-1898. doi: 10.3324/haematol.2017.186387. Epub 2018 Jul 5.

20.

A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.

Tam CS, LeBlond V, Novotny W, Owen RG, Tedeschi A, Atwal S, Cohen A, Huang J, Buske C.

Future Oncol. 2018 Sep;14(22):2229-2237. doi: 10.2217/fon-2018-0163. Epub 2018 Jun 5.

21.

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.

Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia.

N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1.

22.

Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.

Zimmermann H, Babel N, Dierickx D, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Bachy E, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S, Trappe RU.

Transplantation. 2018 Nov;102(11):1914-1923. doi: 10.1097/TP.0000000000002269.

PMID:
29757894
23.

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study.

Stilgenbauer S, Leblond V, Foà R, Böttcher S, Ilhan O, Knauf W, Mikuskova E, Renner C, Tausch E, Woszczyk D, Gresko E, Lundberg L, Moore T, Morris T, Robson S, Bosch F.

Leukemia. 2018 Aug;32(8):1778-1786. doi: 10.1038/s41375-018-0146-5. Epub 2018 Apr 27.

24.

How we manage patients with Waldenström macroglobulinaemia.

Simon L, Baron M, Leblond V.

Br J Haematol. 2018 Jun;181(6):737-751. doi: 10.1111/bjh.15202. Epub 2018 Apr 10. Review.

PMID:
29637541
25.

[Renal toxicity of high-dose methotrexate].

Garcia H, Leblond V, Goldwasser F, Bouscary D, Raffoux E, Boissel N, Broutin S, Joly D.

Nephrol Ther. 2018 Apr;14 Suppl 1:S103-S113. doi: 10.1016/j.nephro.2018.02.015. French.

PMID:
29606256
26.

Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.

Feugier P, Aurran T, Mahé B, Letestu R, Nguyen-Khac F, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Cymbalista F, Ross-Weil D, Leprêtre S.

Haematologica. 2018 Jul;103(7):e304-e306. doi: 10.3324/haematol.2017.183350. Epub 2018 Mar 15. No abstract available.

27.

Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study.

Cartron G, Letestu R, Dartigeas C, Tout M, Mahé B, Gagez AL, Ferrant E, Guiu B, Villemagne B, Letuan P, Aurran T, Orsini-Piocelle F, Banos A, Feugier P, Leblond V, de Guibert S, Tournilhac O, Dupuis J, Delmer A, Rouillé V, Ternant D, Leprêtre S.

Haematologica. 2018 Aug;103(8):e356-e359. doi: 10.3324/haematol.2017.182352. Epub 2018 Mar 8. No abstract available.

28.

Age-specific seroprevalence of human polyomavirus 12 and Saint Louis and New Jersey polyomaviruses.

Gaboriaud P, Ferté M, Arnold F, Leblond V, Nicol J, Debare H, Le Meur M, Martini F, Tognon M, Touzé A.

Emerg Microbes Infect. 2018 Mar 7;7(1):22. doi: 10.1038/s41426-018-0026-0.

29.

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.

Michallet AS, Aktan M, Hiddemann W, Ilhan O, Johansson P, Laribi K, Meddeb B, Moreno C, Raposo J, Schuh A, Ünal A, Widenius T, Bernhardt A, Kellershohn K, Messeri D, Osborne S, Leblond V.

Haematologica. 2018 Apr;103(4):698-706. doi: 10.3324/haematol.2017.170480. Epub 2018 Feb 1.

30.

Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies.

Leclerc E, Combarel D, Uzunov M, Leblond V, Funck-Brentano C, Zahr N.

Sci Rep. 2018 Jan 26;8(1):1681. doi: 10.1038/s41598-018-20136-3.

31.

Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.

Dartigeas C, Van Den Neste E, Léger J, Maisonneuve H, Berthou C, Dilhuydy MS, De Guibert S, Leprêtre S, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, Rodon P, Aurran-Schleinitz T, Vilque JP, Tournilhac O, Mahé B, Laribi K, Michallet AS, Delmer A, Feugier P, Lévy V, Delépine R, Colombat P, Leblond V; CLL 2007 SA investigators; French Innovative Leukemia Organization (FILO).

Lancet Haematol. 2018 Feb;5(2):e82-e94. doi: 10.1016/S2352-3026(17)30235-1. Epub 2017 Dec 20.

PMID:
29275118
32.

Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).

Godet S, Protin C, Dupuis J, Dartigeas C, Bastie JN, Herbaux C, Leblond V, de Guibert S, Ghez D, Brion A, Ysebaert L, Delmer A, Quinquenel A.

Am J Hematol. 2018 Feb;93(2):E52-E54. doi: 10.1002/ajh.24981. Epub 2017 Dec 4. No abstract available.

33.

Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome.

Steinbrecher D, Jebaraj BMC, Schneider C, Edelmann J, Cymbalista F, Leblond V, Delmer A, Ibach S, Tausch E, Scheffold A, Bloehdorn J, Hallek M, Dreger P, Döhner H, Stilgenbauer S.

Leuk Lymphoma. 2018 Jul;59(7):1614-1623. doi: 10.1080/10428194.2017.1390236. Epub 2017 Oct 24.

PMID:
29063805
34.

Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO group.

Guillermin Y, Herbaux C, Subtil F, Aurran-Schleinitz T, Cymbalista F, Letestu R, Leprêtre S, Vaudaux S, Laribi K, Leblond V, Defoi Y, Benchikh R, Salles G, Godmer P, Jardel H, Vallais F, Feugier P, Orsini F, Pegourié B, Lévy V, Michallet AS.

Am J Hematol. 2018 Jan;93(1):E24-E27. doi: 10.1002/ajh.24951. Epub 2017 Nov 17. No abstract available.

35.

Unexpected Pneumocystis jirovecii pneumonia in patients with untreated chronic lymphocytic leukemia.

Sesé L, Rivaud E, Bron C, Leblond V, Raffoux E, Longchampt E, Cahen P, Zemoura L, Mellot F, Couderc LJ, Catherinot E; Foch Hospital Lung Immune Deficiencies study group.

Leuk Lymphoma. 2018 Apr;59(4):1004-1007. doi: 10.1080/10428194.2017.1357170. Epub 2017 Aug 3. No abstract available.

PMID:
28771054
36.

Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).

Durot E, Tomowiak C, Michallet AS, Dupuis J, Hivert B, Leprêtre S, Toussaint E, Godet S, Merabet F, Van Den Neste E, Ivanoff S, Roussel X, Zini JM, Regny C, Lemal R, Sutton L, Perrot A, Le Dû K, Kanagaratnam L, Morel P, Leblond V, Delmer A.

Br J Haematol. 2017 Nov;179(3):439-448. doi: 10.1111/bjh.14881. Epub 2017 Aug 2.

PMID:
28770576
37.

Impact of plerixafor (mozobil) on hospital efficiency: A single center experience.

Azar N, Ouzegdouh M, Choquet S, Leblond V.

J Clin Apher. 2018 Feb;33(1):5-13. doi: 10.1002/jca.21551. Epub 2017 Apr 28.

PMID:
28455878
38.

A transition from using multi-step procedures to a fully integrated system for performing extracorporeal photopheresis: A comparison of costs and efficiencies.

Azar N, Leblond V, Ouzegdouh M, Button P.

J Clin Apher. 2017 Dec;32(6):474-478. doi: 10.1002/jca.21542. Epub 2017 Apr 17.

39.

A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.

Leblond V, Morel P, Dilhuidy MS, Leleu X, Soussain C, Leprête S, Dreyfus B, Dartigeas C, Mahé B, Anglaret B, Pégourié B, Besson C, Aurran T, Vekhoff A, Tournilhac O, Banos A, Oya H, Lejeune J, Ouzegdouh M, Chevret S; French Innovative Leukemia Organization (FILO).

Leuk Lymphoma. 2017 Nov;58(11):2615-2623. doi: 10.1080/10428194.2017.1307357. Epub 2017 Apr 10.

PMID:
28395585
40.

Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1.

Cosson A, Chapiro E, Bougacha N, Lambert J, Herbi L, Cung HA, Algrin C, Keren B, Damm F, Gabillaud C, Brunelle-Navas MN, Davi F, Merle-Béral H, Le Garff-Tavernier M, Roos-Weil D, Choquet S, Uzunov M, Morel V, Leblond V, Maloum K, Lepretre S, Feugier P, Lesty C, Lejeune J, Sutton L, Landesman Y, Susin SA, Nguyen-Khac F.

Leukemia. 2017 Jul;31(7):1625-1629. doi: 10.1038/leu.2017.100. Epub 2017 Mar 27. No abstract available.

PMID:
28344316
41.

Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes.

Martino R, Henseler A, van Lint M, Schaap N, Finke J, Beelen D, Vigouroux S, Alessandrino EP, Mufti GJ, Veelken JH, Bruno B, Yakoub-Agha I, Volin L, Maertens J, Or R, Leblond V, Rovira M, Kalhs P, Alvarez AF, Vitek A, Sierra J, Wagner E, Robin M, de Witte T, Kröger N.

Bone Marrow Transplant. 2017 Aug;52(8):1107-1112. doi: 10.1038/bmt.2017.19. Epub 2017 Mar 20.

PMID:
28319072
42.

Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.

Michallet AS, Campidelli A, Lequeu H, Dilhuydy MS, Tournilhac O, Fornecker LM, Dupuis J, Cymbalista F, De Guibert S, Delmer A, Vilque JP, Ghez D, Leblond V, Subtil F, Feugier P, Ysebaert L.

Am J Hematol. 2017 Jun;92(6):E105-E107. doi: 10.1002/ajh.24715. Epub 2017 Apr 29. No abstract available.

43.

Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel.

D'Sa S, Kersten MJ, Castillo JJ, Dimopoulos M, Kastritis E, Laane E, Leblond V, Merlini G, Treon SP, Vos JM, Lunn MP.

Br J Haematol. 2017 Mar;176(5):728-742. doi: 10.1111/bjh.14492. Epub 2017 Feb 15.

PMID:
28198999
44.

miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.

Gagez AL, Duroux-Richard I, Leprêtre S, Orsini-Piocelle F, Letestu R, De Guibert S, Tuaillon E, Leblond V, Khalifa O, Gouilleux-Gruart V, Banos A, Tournilhac O, Dupuis J, Jorgensen C, Cartron G, Apparailly F.

Haematologica. 2017 Apr;102(4):746-754. doi: 10.3324/haematol.2016.153189. Epub 2017 Jan 25.

45.

Trichodysplasia Spinulosa Polyomavirus Infection Occurs during Early Childhood with Intrafamilial Transmission, Especially from Mother to Child.

Pedergnana V, Martel-Jantin C, Nicol JTJ, Leblond V, Tortevoye P, Coursaget P, Touzé A, Abel L, Gessain A.

J Invest Dermatol. 2017 May;137(5):1181-1183. doi: 10.1016/j.jid.2016.12.017. Epub 2017 Jan 17. No abstract available.

46.

Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.

Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S.

J Clin Oncol. 2017 Feb 10;35(5):536-543. doi: 10.1200/JCO.2016.69.3564. Epub 2016 Dec 19.

PMID:
27992268
47.

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia.

Lancet Oncol. 2017 Feb;18(2):241-250. doi: 10.1016/S1470-2045(16)30632-5. Epub 2016 Dec 10.

PMID:
27956157
48.

Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia.

Algrin C, Golmard JL, Michallet M, Reman O, Huynh A, Perrot A, Sirvent A, Plesa A, Salaun V, Béné MC, Bories D, Tournilhac O, Merle-Béral H, Leblond V, Le Garff-Tavernier M, Dhedin N.

Eur J Haematol. 2017 Apr;98(4):363-370. doi: 10.1111/ejh.12836. Epub 2017 Jan 30.

PMID:
27943415
49.

First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.

Meunier G, Ysebaert L, Nguyen-Thi PL, Lepretre S, Quinquenel A, Dupuis J, Lemal R, Aurran T, Tomowiak C, Cymbalista F, Dilhuydy MS, Brion A, Morel P, Cazin B, Leblond V, Cartron G, Ré D, Béné MC, Michallet AS, Feugier P.

Hematol Oncol. 2017 Dec;35(4):671-678. doi: 10.1002/hon.2370. Epub 2016 Nov 22.

PMID:
27878835
50.

Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.

Wanquet A, Birsen R, Bonnet C, Boubaya M, Choquet S, Dupuis J, Lepretre S, Re D, Fahri J, Michallet AS, Ysebaert L, Lemal R, Lamy T, Delarue R, Troussard X, Cymbalista F, Levy V, Dietrich PY, Leblond V, Aurran-Schleinitz T.

Br J Haematol. 2017 Jan;176(1):37-49. doi: 10.1111/bjh.14387. Epub 2016 Nov 11.

PMID:
27858991

Supplemental Content

Loading ...
Support Center